Xenon Pharmaceuticals Inc. (XENE) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Engine safety override at $53.71: Quality below floor (1.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.5/10 and A.R:R 4.6:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality.
Xenon Pharmaceuticals is a neuroscience biopharma advancing azetukalner, a Kv7 potassium channel opener, through Phase 3 studies for focal onset seizures, PGTCS, MDD, and bipolar depression. Also has early-stage pain programs (XEN1701, XEN1120). No marketed products; revenue... Read more
Sell if holding. Engine safety override at $53.71: Quality below floor (1.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.5/10 and A.R:R 4.6:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 5.5/10, moderate confidence.
Passes 7/8 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news boost analyst 0.70, earnings proximity 84d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: moderate.
Recent Developments — Xenon Pharmaceuticals Inc.
Latest news
- JP Morgan Maintains Overweight on Xenon Pharmaceuticals, Raises Price Target to $80 — benzinga May 12, 2026 positive
- RBC Capital Maintains Outperform on Xenon Pharmaceuticals, Raises Price Target to $82 — benzinga May 8, 2026 positive
- Needham Maintains Buy on Xenon Pharmaceuticals, Lowers Price Target to $78 — benzinga May 8, 2026 positive
- Xenon Pharmaceuticals Q1 EPS $(1.17) Beats $(1.20) Estimate, Cash, Cash Equivalents And Marketable Securities Of $1.3B E — benzinga May 7, 2026 positive
- Reported Sunday, Xenon Presents Phase 3 X-TOLE2 Data Showing Azetukalner Delivers 53.2% Reduction In Monthly Seizure Fre — benzinga Apr 20, 2026 positive
Generated 2026-05-20T21:06:21Z.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHpipelineazetukalner10-K Item 1A: 'We have no marketed proprietary products and are advancing clinical development through Phase 3 clinical studies for our azetukalner program in epilepsy, major depressive disorder, and bipolar depression.'
Material Events(8-K, last 90d)
- 2026-04-13Item 5.02LOWCompany amended 2025 Inducement Equity Incentive Plan, increasing reserved shares from 900,000 to 1,175,000 for employee inducement grants. Routine compensatory arrangement change; no officer departure or appointment.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
2 floor-breakers·2 ceiling hits
Quality below the gate floor. Component breakdown shows what dragged the score down.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $53.71: Quality below floor (1.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.5/10 and A.R:R 4.6:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $51.57. Score 5.5/10, moderate confidence.
Take-profit target: $71.27 (+32.7% upside). Prior stop was $51.57. Stop-loss: $51.57.
Concentration risk — Pipeline: azetukalner; Quality below floor (1.5 < 4.0).
Xenon Pharmaceuticals Inc. trades at a P/E of N/A (forward -10.9). TrendMatrix value score: 9.0/10. Verdict: Sell.
26 analysts cover XENE with a consensus score of 4.4/5. Average price target: $79.
What does Xenon Pharmaceuticals Inc. do?Xenon Pharmaceuticals is a neuroscience biopharma advancing azetukalner, a Kv7 potassium channel opener, through Phase...
Xenon Pharmaceuticals is a neuroscience biopharma advancing azetukalner, a Kv7 potassium channel opener, through Phase 3 studies for focal onset seizures, PGTCS, MDD, and bipolar depression. Also has early-stage pain programs (XEN1701, XEN1120). No marketed products; revenue comes from a Neurocrine Biosciences collaboration on sodium channel inhibitors.